The Role of CD34 + Stem Cells and Biomarkers in the Development of CAV in HTX Patients

Heart Transplant Failure Clinical Trial

Official title: The Role of CD34 + Stem Cells and Biological Markers of Angiogenesis in the Development of Coronary Allograft Vasculopathy in Patients After Heart Transplantation

Status Completed

Clinical Trial Summary

Coronary allograft vasculopathy represents one of the major limiting factors of long-term survival in heart transplant recipients. While extensively researched, the underlying mechanisms of coronary allograft vasculopathy (CAV) after heart transplantation remain incompletely understood. As CD34+ cells represent one of the key determinants of coronary vascular homeostasis we investigated the potential association between CAV and CD34+ cell count in heart transplant recipients.

Clinical Trial Description

In a single-center prospective pilot cohort study, we aim to enroll 55 adult heart transplant recipients. All patients will undergo coronary CT angiography and the presence of CAV will be defined in accordance with the ISHLT criteria. At the time of CT angiography, patient will undergo detailed clinical evaluation, cardiac echo and we will also collect blood samples, perform extensive biochemical analysis and measure CD34+ cell count in peripheral venous blood using Beckman-Coulter Navios EX flow cytometry with standard antibodies according to ISAGE protocol. Biomarkers of angiogenesis will be evaluated using Luminex assay kit. ;

Related Conditions & MeSH terms

• Heart Transplant Failure
• Vascular Diseases
• Vasculopathy

• NCT number: NCT05485467
• Study type: Observational
• Source: University Medical Centre Ljubljana
• Status: Completed
• Start date: June 1, 2022
• Completion date: August 31, 2022